[vc_row full_width=”stretch_row_content_no_spaces” content_placement=”middle” css=”.vc_custom_1556108564202{background-image: url(https://www.selectimmune.com/wp-content/uploads/2019/04/projects_1.jpg?id=371) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” el_class=”min-h-70vh”][vc_column][vc_column_text]
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text inpublix_narrow_column=”1″]
Infections continue to threaten human health as pathogenic organisms outsmart available therapies with remarkable genetic versatility. Fortunately, microbial versatility is matched by the flexibility of the host immune system, which provides a rich source of novel therapeutic concepts.
Our therapeutic strategy is to find and develop substances that strengthen the immune system.
Rather than drugs killing the bacteria directly the patient’s immune system is empowered to deal with the bacteria.
Our goal is to provide a different molecular framework for the treatment of bacterial infections; much needed to combat antibiotic resistance.
[/vc_column_text][/vc_column][/vc_row][vc_row equal_height=”yes”][vc_column width=”1/4″ css=”.vc_custom_1556092004313{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_single_image image=”260″ img_size=”250×220″][vc_column_text]
IL-1 receptor antagonists to treat acute infections and prevent tissue damage
[/vc_column_text][/vc_column][vc_column width=”1/4″ css=”.vc_custom_1556092339693{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_single_image image=”265″ img_size=”250×220″][vc_column_text]
A nerve cell receptor antagonist prevents prevents pain and tissue damage during acute infections
[/vc_column_text][/vc_column][vc_column width=”1/4″ css=”.vc_custom_1556092379385{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_single_image image=”259″ img_size=”250×220″][vc_column_text]
A small molecule from ”nice bacteria” prevents over-activation of immunity and reduces inflammation
[/vc_column_text][/vc_column][vc_column width=”1/4″ css=”.vc_custom_1556092403938{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_single_image image=”255″ img_size=”250×220″][vc_column_text]
New molecular tools to inhibit ‘’bad’’ inflammation in infected tissue and reduce the risk of sepsis
[/vc_column_text][/vc_column][/vc_row][vc_row full_width=”stretch_row_content” css=”.vc_custom_1622462807226{background-color: #e2e2e2 !important;}”][vc_column][vc_column_text inpublix_narrow_column=”1″]
[/vc_column_text][vc_column_text inpublix_narrow_column=”1″]
Butler, D. et al. Review Article, Nature Reviews Urology, doi:10.1038/s41585-022-00602-4 (2022).
PDF: NRU 2022
Wullt, B. et al. European Urology Open Science, 31, 49-58, doi:10.1016/j.euros.2021.07.003 (2021).
Ambite, I. et al. Letter to the Editor, The Journal of Clinical Investigation 131(18):e153234 doi:10.1172/JCI153234 (2021).
PDF: JCI letter to the Editor 2021
Ambite, I. et al. Review Article, Nature Reviews Urology 18, 468–486, doi:10.1038/s41585-021-00477-x (2021).
PDF: NRU 2021
Ambite, I. et al. The Journal of Clinical Investigation 131(4), e140333, doi:10.1172/JCI140333 (2021).
PDF: JCI 2021
Butler, D.S.C. et al. Scientific Reports 8, 11015, doi:10.1038/s41598-018-28634-0 (2018).
PDF: Sci reports 2018
Puthia, M. et al. Science Translational Medicine 8(336), 336ra59, doi:10.1126/scitranslmed.aaf1156 (2016).
PDF: Sci Trans Med 2016
Ambite, I. et al. PLoS Pathogens 12(10), e1005848, doi:10.1371/journal.ppat.1005848 (2016).
PDF: Plos Pathogens 2016
Lutay, N. et al. The Journal of Clinical Investigation 123(6), 2366-79, doi:10.1172/JCI6645 (2013).
PDF: JCI 2013[/vc_column_text][/vc_column][/vc_row]